Related Experiment Video
Updated: Dec 25, 2025
10:43
Evaluating In Vitro DNA Damage Using Comet Assay
Published on: October 11, 2017
39.2K
Olaparib for advanced breast cancer
Gaia Griguolo1,2, Maria Vittoria Dieci1,2, Federica Miglietta1,2
1Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
Future Oncology (London, England)
|April 7, 2020
Summary
Olaparib, a PARP-inhibitor, offers clinical benefits for HER2-negative advanced breast cancer patients with BRCA1/2 mutations. It significantly improves progression-free survival and shows overall survival benefits in specific patient groups.
Area of Science:
- Oncology
- Pharmacology
Background:
- Olaparib is an oral poly (ADP-ribose) polymerase (PARP) inhibitor.
- Germline BRCA1/2 mutations are associated with HER2-negative advanced breast cancer.
- PARP inhibitors represent a targeted therapy approach for specific cancer types.
Purpose of the Study:
- To review preclinical, pharmacokinetic, and pharmacodynamic data of olaparib.
- To evaluate the clinical efficacy and tolerability of olaparib in breast cancer.
- To discuss future directions, including biomarker selection and combination therapies.
Main Methods:
- Review of preclinical studies on olaparib.
- Analysis of pharmacokinetic and pharmacodynamic data.
- Examination of clinical trial data, including a Phase III randomized trial.
Main Results:
- Olaparib demonstrated significant progression-free survival benefit compared to chemotherapy in a Phase III trial.
- An overall survival benefit was observed in patients not previously treated with chemotherapy for metastatic disease.
- Olaparib shows antitumor efficacy as monotherapy and in combination treatments.
Conclusions:
- Olaparib is a clinically beneficial option for HER2-negative advanced breast cancer patients with germline BRCA1/2 mutations.
- Further research is needed on optimal patient selection biomarkers and combination strategies.
- Olaparib offers a targeted treatment approach with a favorable efficacy and tolerability profile.
More Related Videos
Related Concept Videos
02:56Treatment Resistant Cancers
3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:49Cancer Therapies
9.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
02:50Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
02:34Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
02:37Restarting Stalled Replication Forks
6.2K
DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart,...
6.2K